Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Socazolimab Combined With Capecitabine in Adjuvant Biliary Tract Cancer
NCT04608786Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Feb 2021
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of socazolimab in biliary tract cancer (BTC), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoints: Dose Limiting Toxicity at 21 days and Recommended Phase II Dose at 21 days. Status: unknown.
02
Drugs
socazolimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04608786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04608786.